Kukje Pharma Statistics
Total Valuation
Kukje Pharma has a market cap or net worth of KRW 92.04 billion. The enterprise value is 112.80 billion.
Market Cap | 92.04B |
Enterprise Value | 112.80B |
Important Dates
The last earnings date was Monday, March 17, 2025.
Earnings Date | Mar 17, 2025 |
Ex-Dividend Date | Mar 13, 2025 |
Share Statistics
Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 0.27% in one year.
Current Share Class | n/a |
Shares Outstanding | 20.36M |
Shares Change (YoY) | +0.27% |
Shares Change (QoQ) | -0.56% |
Owned by Insiders (%) | 12.78% |
Owned by Institutions (%) | 8.41% |
Float | 12.69M |
Valuation Ratios
The trailing PE ratio is 17.66.
PE Ratio | 17.66 |
Forward PE | n/a |
PS Ratio | 0.59 |
PB Ratio | 1.02 |
P/TBV Ratio | 1.04 |
P/FCF Ratio | 89.46 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.39, with an EV/FCF ratio of 109.64.
EV / Earnings | 21.67 |
EV / Sales | 0.72 |
EV / EBITDA | 11.39 |
EV / EBIT | 16.83 |
EV / FCF | 109.64 |
Financial Position
The company has a current ratio of 2.00, with a Debt / Equity ratio of 0.33.
Current Ratio | 2.00 |
Quick Ratio | 1.13 |
Debt / Equity | 0.33 |
Debt / EBITDA | 2.98 |
Debt / FCF | 28.68 |
Interest Coverage | 5.56 |
Financial Efficiency
Return on equity (ROE) is 5.97% and return on invested capital (ROIC) is 3.57%.
Return on Equity (ROE) | 5.97% |
Return on Assets (ROA) | 2.55% |
Return on Invested Capital (ROIC) | 3.57% |
Return on Capital Employed (ROCE) | 4.89% |
Revenue Per Employee | 641.24M |
Profits Per Employee | 21.33M |
Employee Count | 244 |
Asset Turnover | 0.95 |
Inventory Turnover | 3.39 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.92% in the last 52 weeks. The beta is 0.73, so Kukje Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.73 |
52-Week Price Change | -20.92% |
50-Day Moving Average | 4,932.10 |
200-Day Moving Average | 5,429.75 |
Relative Strength Index (RSI) | 26.10 |
Average Volume (20 Days) | 86,029 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kukje Pharma had revenue of KRW 156.46 billion and earned 5.21 billion in profits. Earnings per share was 256.00.
Revenue | 156.46B |
Gross Profit | 82.50B |
Operating Income | 6.70B |
Pretax Income | 6.61B |
Net Income | 5.21B |
EBITDA | 9.90B |
EBIT | 6.70B |
Earnings Per Share (EPS) | 256.00 |
Balance Sheet
The company has 8.75 billion in cash and 29.51 billion in debt, giving a net cash position of -20.76 billion or -1,019.36 per share.
Cash & Cash Equivalents | 8.75B |
Total Debt | 29.51B |
Net Cash | -20.76B |
Net Cash Per Share | -1,019.36 |
Equity (Book Value) | 89.55B |
Book Value Per Share | 4,422.21 |
Working Capital | 28.43B |
Cash Flow
In the last 12 months, operating cash flow was 3.94 billion and capital expenditures -2.91 billion, giving a free cash flow of 1.03 billion.
Operating Cash Flow | 3.94B |
Capital Expenditures | -2.91B |
Free Cash Flow | 1.03B |
FCF Per Share | 50.53 |
Margins
Gross margin is 52.73%, with operating and profit margins of 4.28% and 3.33%.
Gross Margin | 52.73% |
Operating Margin | 4.28% |
Pretax Margin | 4.22% |
Profit Margin | 3.33% |
EBITDA Margin | 6.33% |
EBIT Margin | 4.28% |
FCF Margin | 0.66% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.65%.
Dividend Per Share | 30.00 |
Dividend Yield | 0.65% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 5 |
Payout Ratio | n/a |
Buyback Yield | -0.27% |
Shareholder Yield | 0.37% |
Earnings Yield | 5.66% |
FCF Yield | 1.12% |
Stock Splits
The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.
Last Split Date | Mar 17, 2023 |
Split Type | Forward |
Split Ratio | 1.05 |
Scores
Kukje Pharma has an Altman Z-Score of 2.19. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.19 |
Piotroski F-Score | n/a |